Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • kidney cancer

    - PMLiVE

    Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

    Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

    - PMLiVE

    Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

    Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

    Weinreich brings clinical development and venture capital experience to the role

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

    Innovative Trials

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

    A new restructuring programme has been approved to support the initiative

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links